Fulcrum Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Fulcrum Therapeutics is de winst gegroeid met een gemiddeld jaarlijks percentage van 11.1%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 12.2%. De inkomsten zijn gegroeid met een gemiddelde van 8.8% per jaar.
Belangrijke informatie
11.12%
Groei van de winst
26.83%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 5.95% |
| Inkomstengroei | 8.79% |
| Rendement op eigen vermogen | -27.36% |
| Nettomarge | n/a |
| Laatste winstupdate | 30 Jun 2026 |
Recente prestatie-updates uit het verleden
Recent updates
FULC: Cash And Optionality Review Will Shape Post-Program Restructuring Path
Fulcrum Therapeutics' analyst fair value estimate moved from $16.75 to $4.00 as analysts cut modeled expectations following the discontinuation of pociredir in sickle cell disease and shifted focus toward the company's cash position and ongoing review of alternatives. Analyst Commentary Recent Street research on Fulcrum Therapeutics has shifted sharply following the decision to discontinue pociredir in sickle cell disease, with most firms now treating the stock as primarily a cash and optionality story rather than a late stage development story.
FULC: Cash-Rich Balance Sheet Will Underpin Post-Program Strategic Review Outcomes
Analysts have reset expectations on Fulcrum Therapeutics, with price targets now clustered in the $3 to $4 range. This reflects the removal of pociredir from models and a focus on the company’s cash position and ongoing review of options.Fulcrum Therapeutics: Buy It For The Strategic Reset
Summary Fulcrum is trading at a deep discount due to operational distress after the suspension of their main program. But because of their fortress balance sheet, Fulcrum should have the financial strength to reset. Fulcrum is a financially strong company in operational distress, and it's trading below NCAV, making it comparable to issues that have strongly outperformed the market. Read the full article on Seeking AlphaFULC: Cash Review And Restructuring Will Drive Future Share Repricing
Fulcrum Therapeutics' analyst fair value estimate has been revised from $25.00 to about $16.75 as analysts factor in widespread rating downgrades and sharply reduced price targets, following the discontinuation of the pociredir program in sickle cell disease and the shift toward a cash-focused review of options. Analyst Commentary Recent research on Fulcrum Therapeutics points to a broad reset in expectations after the discontinuation of pociredir in sickle cell disease, with multiple firms revising ratings and price targets, and several explicitly framing the stock more as a cash-focused situation during the current review of options.FULC: Cash-Rich Balance Sheet Will Shape Post-Program Review Outcome
The updated analyst price target for Fulcrum Therapeutics has shifted sharply lower, with the fair value estimate moving from about $19.00 to roughly $5.43. Analysts are factoring in the discontinuation of pociredir in sickle cell disease, class-wide safety concerns around PRC2 inhibitors, and the company's transition into a cash-focused story undergoing a review of alternatives.Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. By way of example, Fulcrum...Fetal Hemoglobin Induction Will Reshape Sickle Cell Care And Broaden Long Term Hematology Potential
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on small molecule treatments for genetically defined diseases, with an emphasis on sickle cell disease and hematologic conditions. What are the underlying business or industry changes driving this perspective?Oral Fetal Hemoglobin Induction Will Reshape Severe Sickle Cell Treatment Over The Long Term
Catalysts About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical stage biopharmaceutical company focused on developing oral fetal hemoglobin inducers for sickle cell disease and other hemoglobinopathies. What are the underlying business or industry changes driving this perspective?We're Not Very Worried About Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Fulcrum Therapeutics...Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Business And Shares Still Trailing The Industry
You may think that with a price-to-sales (or "P/S") ratio of 1.7x Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) is a stock...There's Reason For Concern Over Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Massive 34% Price Jump
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders have had their patience rewarded with a 34% share price jump in...We Think Fulcrum Therapeutics (NASDAQ:FULC) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%
Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ) shareholders that were waiting for something to happen have been dealt a...Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly
Summary Fulcrum Therapeutics, Inc.'s stock plummeted over 60% after its lead candidate, losmapimod, failed to meet primary and secondary endpoints in a Phase 3 study for FSHD. Despite prior optimism and significant investments from Sanofi and positive analyst ratings, the REACH trial's results were disappointing, leading to the suspension of the losmapimod program. Fulcrum's management, facing leadership changes and a challenging market, will now focus on its other clinical-stage candidate, pociredir, for sickle cell disease. With a market cap of $550m and nearly $300m in cash, the future value of Fulcrum's pipeline remains uncertain amidst intense competition. Read the full article on Seeking AlphaWill Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Fulcrum...Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today
The latest analyst coverage could presage a bad day for Fulcrum Therapeutics, Inc. ( NASDAQ:FULC ), with the analysts...We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Opbrengsten en kosten
Hoe Fulcrum Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 26 | 0 | -85 | 30 | 0 |
| 31 Mar 26 | 0 | -76 | 30 | 0 |
| 31 Dec 25 | 0 | -75 | 29 | 0 |
| 30 Sep 25 | 0 | -71 | 29 | 25 |
| 30 Jun 25 | 0 | -73 | 30 | 25 |
| 31 Mar 25 | 80 | -1 | 33 | 0 |
| 31 Dec 24 | 80 | -10 | 36 | 0 |
| 30 Sep 24 | 81 | -18 | 39 | 0 |
| 30 Jun 24 | 82 | -20 | 40 | 0 |
| 31 Mar 24 | 3 | -99 | 40 | 0 |
| 31 Dec 23 | 3 | -97 | 42 | 0 |
| 30 Sep 23 | 3 | -99 | 42 | 0 |
| 30 Jun 23 | 3 | -98 | 42 | 0 |
| 31 Mar 23 | 4 | -109 | 42 | 0 |
| 31 Dec 22 | 6 | -110 | 42 | 0 |
| 30 Sep 22 | 11 | -107 | 41 | 0 |
| 30 Jun 22 | 14 | -104 | 40 | 0 |
| 31 Mar 22 | 17 | -90 | 36 | 0 |
| 31 Dec 21 | 19 | -81 | 31 | 0 |
| 30 Sep 21 | 18 | -75 | 27 | 0 |
| 30 Jun 21 | 15 | -73 | 23 | 0 |
| 31 Mar 21 | 13 | -69 | 22 | 0 |
| 31 Dec 20 | 9 | -71 | 21 | 0 |
| 30 Sep 20 | 5 | -69 | 20 | 0 |
| 30 Jun 20 | 3 | -68 | 18 | 0 |
| 31 Mar 20 | 1 | -68 | 16 | 0 |
| 31 Dec 19 | 0 | -90 | 13 | 0 |
| 30 Sep 19 | 0 | -85 | 11 | 7 |
| 30 Jun 19 | 0 | -79 | 10 | 14 |
| 31 Mar 19 | 0 | -71 | 9 | 20 |
| 31 Dec 18 | 0 | -39 | 8 | 25 |
Kwaliteitswinsten: FULC is momenteel verliesgevend.
Groeiende winstmarge: FULC is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: FULC is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 11.1% per jaar verminderd.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van FULC over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: FULC is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( 1% ).
Rendement op eigen vermogen
Hoge ROE: FULC heeft een negatief Return on Equity ( -27.36% ), omdat het momenteel verliesgevend is.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/21 04:39 |
| Aandelenkoers aan het einde van de dag | 2026/08/20 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Fulcrum Therapeutics, Inc. wordt gevolgd door 16 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Dae Gon Ha | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |